News – Page 1157 – Endpoints News

Promising or inconclusive? Gilead fields PhII GS-4997 data, triggering more pushback on NASH claims

9 years ago

Puma shares ripped after growing grade 3 diarrhea threat is highlighted in an abstract

9 years ago

Did Merck KGaA’s aging atacicept just fail a PhIIb lupus trial? Well, yes, but…

9 years ago

Novartis’ ‘breakthrough’ AML drug gets accelerated FDA review; Ocular surges on positive PhIII eye study

9 years ago

Step 3: Sanofi commits up to $100M to opt-in on Alnylam’s PhIII RNAi hemophilia trial

9 years ago

Dynavax shares crater after the FDA rejects Heplisav-B, again, and CEO signals for help

9 years ago

Under a short assault, Corbus counterattacks with positive PhII data for systemic sclerosis drug

9 years ago

J&J, GSK stumble coming out of the gate with mixed PhIII rheumatoid arthritis data for sirukumab

9 years ago

Biotech insider Rich Bagger is out, Gingrich is up in latest reshuffle of Trump’s inner circle

9 years ago

Bristol-Myers partners with Johns Hopkins on Opdivo pact; A Valeant by any other name…

9 years ago

The longterm implications of the Trump Bump; Let’s try again on drug pricing

9 years ago

Polaris cashes in its chips as Langer-backed Arsia is auctioned off to Eagle for up to $78M

9 years ago

Ultragenyx nixes plan to seek quick OK for rare disease drug in Europe

9 years ago

PTC shares rocket up as European regulators offer a thumbs-up on Duchenne drug marketing

9 years ago

Donald Trump sends a vaguely worded love letter to biopharma as stock rally continues

9 years ago

Kleiner Perkins-backed Elcelyx says its reformulated metformin worked in a PhIIb diabetes study

9 years ago

Adaptimmune surges after FDA lifts partial hold; Anthera tanks on PhIII flop; Kadmon axes staffers in restructuring

9 years ago

Bristol-Myers scores fresh bragging rights with PhIII gastric cancer success for Opdivo

9 years ago

Bristol-Myers hands over $100M in cash for a new fibrosis drug, beefing up NASH focus

9 years ago

Cell Medica signs up for an off-the-shelf CAR-T collaboration with Baylor

9 years ago

AstraZeneca axes another R&D track on durvalumab after once again falling behind rivals

9 years ago

Crushed by a PhIII flop, Novavax slashes jobs as it looks to chop out up to $100M in costs

9 years ago

Celgene EVP Rich Bagger makes Politico’s short list for Trump’s Cabinet

9 years ago

Bristol-Myer's Opdivo teams up with Infinity's last hope

9 years ago

First page Previous page 1154 1155 115611571158 1159 1160 Next page Last page